These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 19196196)
21. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165 [TBL] [Abstract][Full Text] [Related]
22. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Rendi-Wagner P; Paulke-Korinek M; Kundi M; Burgmann H; Georgopoulos A; Vécsei A; Kollaritsch H Vaccine; 2009 Jun; 27(30):3963-8. PubMed ID: 19393711 [TBL] [Abstract][Full Text] [Related]
23. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants. Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934 [TBL] [Abstract][Full Text] [Related]
25. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924 [TBL] [Abstract][Full Text] [Related]
26. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine. Winther TN; Kristensen TD; Kaltoft MS; Konradsen HB; Knudsen JD; Høgh B Acta Paediatr; 2009 Feb; 98(2):328-31. PubMed ID: 18983440 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease. Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089 [TBL] [Abstract][Full Text] [Related]
30. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Hsieh YC; Lin PY; Chiu CH; Huang YC; Chang KY; Liao CH; Chiu NC; Chuang YC; Chen PY; Chang SC; Liu JW; Yen MY; Wang JH; Liu CY; Lin TY Vaccine; 2009 Sep; 27(40):5513-8. PubMed ID: 19615960 [TBL] [Abstract][Full Text] [Related]
31. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095 [TBL] [Abstract][Full Text] [Related]
32. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301 [TBL] [Abstract][Full Text] [Related]
33. Declining invasive pneumococcal disease in the U.S. elderly. McBean AM; Park YT; Caldwell D; Yu X Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366 [TBL] [Abstract][Full Text] [Related]
35. Impact of the conjugate pneumococcal vaccine in arkansas. Schutze GE; Tucker NC; Mason EO Pediatr Infect Dis J; 2004 Dec; 23(12):1125-9. PubMed ID: 15626950 [TBL] [Abstract][Full Text] [Related]
36. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Ardanuy C; Tubau F; Pallares R; Calatayud L; Domínguez MA; Rolo D; Grau I; Martín R; Liñares J Clin Infect Dis; 2009 Jan; 48(1):57-64. PubMed ID: 19035779 [TBL] [Abstract][Full Text] [Related]
37. Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts. Nuorti JP; Martin SW; Smith PJ; Moran JS; Schwartz B Am J Prev Med; 2008 Jan; 34(1):46-53. PubMed ID: 18083450 [TBL] [Abstract][Full Text] [Related]
38. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Aguiar SI; Serrano I; Pinto FR; Melo-Cristino J; Ramirez M; Clin Microbiol Infect; 2008 Sep; 14(9):835-43. PubMed ID: 18844684 [TBL] [Abstract][Full Text] [Related]
39. [Invasive pneumoccal disease in children in Oslo 1998-2004]. Brauteset LV; Høiby EA; Syversen G; Surén P; Wathne KO Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1380-3. PubMed ID: 18552897 [TBL] [Abstract][Full Text] [Related]
40. HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--US, 1998-2003. Ann Pharmacother; 2005 Nov; 39(11):1967-8. PubMed ID: 16219891 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]